Study Summary
The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).
Want to learn more about this trial?
Request More InfoInterventions
Fully human anti CD19 CAR-T Cell DoseBIOLOGICAL
Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)
Infusion of CAR-T cells will occur over 5-30 minutes.
FludarabineDRUG
25 mg/m2 daily from day -5 to -3
CyclophosphamideDRUG
60mg/Kg on day -6
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | Cleveland | Ohio | United States |